Waters Corp's India business boosted by rush for weight-loss drugs

May 15, 2025 04:48 AM PDT | By EODHD

Google News:

Waters Corp's India business boosted by rush for weight-loss drugs — Image source: Kalkine Media

Recent News

Yelp Inc Faces Rating Shift Amid NYSE Composite Sector

Cloudastructure (NASDAQ:CSAI) Upgraded Amid Nasdaq Composite Market Mo...

Spire Wealth Management Boosts Sonoco Stake in Russell 1000 Update

First American Financial Corp (NYSE:FAF) Strong on NYSE Composite Mome...

By Kashish Tandon BENGALURU (Reuters) -U.S.-based Waters Corp, which makes medical equipment used in clinical testing, has seen a spurt in demand from drugmakers in India rushing to develop their versions of popular weight-loss drugs, a senior executive told Reuters. Semaglutide, the active ingredient in Novo Nordisk's Wegovy and diabetes medicine Ozempic, goes off patent in India in 2026, paving the way for cheaper versions of the drugs. Local drugmakers including Biocon, Cipla, Dr. Reddy's and Lupin have been racing to make generic versions of these drugs to grab a share of the global market estimated to be worth $150 billion in the next decade. "India will be the leading player in GLP drugs as well because we are in generics and we have manufacturing facilities to support," said T.

Anil Kumar, vice president of Water's India business, referring to the class of weight-loss drugs known as GLP-1 agonists. Waters, based in Milford, Massachusetts, makes laboratory equipment, software and other tools used in clinical testing by drugmakers and biotech companies. Its India unit contributes about 8% to Waters' sales. "A lot of work is coming to India... so I see this as an opportunity for us," Kumar said.

Waters is expecting revenue growth percentage in the double digits in India on the back of these growth drivers, he added. Waters Corp operates nine sites in India with over 430 employees. The company is headquartered in the tech hub of Bengaluru, where it also opened a Global Capability Center in 2023. The company expects annual growth contribution of 70-100 basis points from its India business in the near-term and a 30 basis points boost from testing for GLP-1 drugs. Last week, the company raised its annual profit forecast and reported better-than-expected quarterly results on higher demand in Asia and the Americas.

(Reporting by Kashish Tandon in Bengaluru; Editing by Krishna Chandra Eluri)

Disclaimer

The content, including but not limited to any articles, news, quotes, information, data, text, reports, ratings, opinions, images, photos, graphics, graphs, charts, animations, and video (Content) is a service of Kalkine Media LLC., having Delaware File No. 4697309 (“Kalkine Media, we or us”) and is available for personal and non-commercial use only. The principal purpose of the Content is to educate and inform. The Content does not contain or imply any recommendation or opinion intended to influence your financial decisions and must not be relied upon by you as such. Some of the Content on this website may be sponsored/non-sponsored, as applicable, but is NOT a solicitation or recommendation to buy, sell or hold the stocks of the company(s) or engage in any investment activity under discussion. Kalkine Media is neither licensed nor qualified to provide investment advice through this platform. Users should make their own enquiries about any investments and Kalkine Media strongly suggests the users to seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice), as necessary. Kalkine Media hereby disclaims any and all the liabilities to any user for any direct, indirect, implied, punitive, special, incidental or other consequential damages arising from any use of the Content on this website, which is provided without warranties. The views expressed in the Content by the guests, if any, are their own and do not necessarily represent the views or opinions of Kalkine Media.
The content published on Kalkine Media also includes feeds sourced from third-party providers. Kalkine does not assert any ownership rights over the content provided by these third-party sources. The inclusion of such feeds on the Website is for informational purposes only. Kalkine does not guarantee the accuracy, completeness, or reliability of the content obtained from third-party feeds. Furthermore, Kalkine Media shall not be held liable for any errors, omissions, or inaccuracies in the content obtained from third-party feeds, nor for any damages or losses arising from the use of such content. Some of the images/music that may be used on this website are copyrighted to their respective owner(s). Kalkine Media does not claim ownership of any of the pictures/music displayed/used on this website unless stated otherwise. The images/music that may be used on this website are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source (public domain/CC0 status) to where it was found and indicated it, as necessary.
This disclaimer is subject to change without notice. Users are advised to review this disclaimer periodically for any updates or modifications.